| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 49 companies in the Life Sciences Tools & Services industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2024 | WGS Genedx Holdings Corp. | Feeley Kevin46 | Chief Financial Officer | Sell | 301 | $8.57 | $2,579.57 | -1.3% | +139.4% | +1004.9% | |
| Mar 1, 2024 | EXAS Exact Sciences Corp | Doyle James Edward75 | Director | Sell | 2,000 | $57.50 | $115,000.00 | -3.8% | -23.9% | -20.2% | |
| Mar 1, 2024 | PSNL Personalis, Inc. | Myers Woodrow A Jr | Director | Buy | 10,000 | $1.67 | $16,700.00 | +62.1% | -22.5% | +145.0% | |
| Mar 1, 2024 | EXAS Exact Sciences Corp | Levangie Daniel J | Director | Sell | 5,000 | $57.50 | $287,500.00 | -17.9% | -23.9% | -20.2% | |
| Mar 1, 2024 | IQV Iqvia Holdings Inc. | Bousbib Ari64 | See Remarks | Sell | 31,678 | $250.53 | $7,936,192.56 | -1.9% | -11.9% | -25.2% | |
| Mar 1, 2024 | VCYT Veracyte, Inc. | Jones Evan/ Fa70 | Director | Sell | 10,000 | $24.36 | $243,599.00 | -21.0% | -12.5% | +44.8% | |
| Mar 1, 2024 | EXAS Exact Sciences Corp | Herriott James75 | General Counsel | Sell | 862 | $59.32 | $51,133.84 | -8.6% | -23.9% | -20.2% | |
| Mar 1, 2024 | EXAS Exact Sciences Corp | Conroy Kevin T81 | President And CEO | Sell | 8,271 | $59.32 | $490,635.72 | -0.6% | -23.9% | -20.2% | |
| Mar 1, 2024 | MEDP Medpace Holdings, Inc. | Troendle August J.71 | CEO | Sell | 100,000 | $400.25 | $40,024,600.00 | -1.0% | -4.6% | -19.0% | |
| Mar 1, 2024 | EXAS Exact Sciences Corp | Cunningham Everett54 | Chief Commercial Officer | Sell | 2,412 | $59.32 | $143,079.84 | -5.0% | -23.9% | -20.2% | |
| Mar 1, 2024 | MEDP Medpace Holdings, Inc. | Medpace Investors, LLC69 | 10% Owner | Sell | 100,000 | $400.25 | $40,024,600.00 | -1.0% | -4.6% | -19.0% | |
| Mar 1, 2024 | EXAS Exact Sciences Corp | Elliott Jeffrey Thomas79 | Chief Financial Officer | Sell | 2,412 | $59.32 | $143,079.84 | -18.1% | -23.9% | -20.2% | |
| Mar 1, 2024 | EXAS Exact Sciences Corp | Condella Sarah75 | EVP, Human Resources | Sell | 1,724 | $59.32 | $102,267.68 | -2.2% | -23.9% | -20.2% | |
| Mar 1, 2024 | EXAS Exact Sciences Corp | Baranick Brian75 | Gen. Mgr., Precision Oncology | Sell | 2,323 | $59.32 | $137,800.36 | -14.1% | -23.9% | -20.2% | |
| Mar 1, 2024 | EXAS Exact Sciences Corp | Orville Jacob A76 | General Manager, Screening | Sell | 2,154 | $59.32 | $127,775.28 | -13.1% | -23.9% | -20.2% | |
| Mar 1, 2024 | MEDP Medpace Holdings, Inc. | Ewald Stephen P59 | General Counsel &Corp. Secy. | Sell | 1,513 | $395.19 | $597,922.82 | -5.3% | -4.6% | -19.0% | |
| Feb 29, 2024 | CRL Charles River Laboratories International, Inc. | Parisotto Shannon M67 | Cevp, Disc &Safety Assessment | Sell | 3,786 | $253.45 | $959,544.98 | -24.1% | -16.8% | -35.0% | |
| Feb 29, 2024 | RVTY Revvity, Inc. | Michas Alexis P68 | Director | Sell | 5,000 | $109.98 | $549,900.00 | -8.3% | +0.1% | +2.3% | |
| Feb 29, 2024 | NTRA Natera, Inc. | Sheena Jonathan46 | Director, Co-founder | Sell | 16,000 | $87.72 | $1,403,542.01 | -0.8% | +27.0% | +79.9% | |
| Feb 29, 2024 | MEDP Medpace Holdings, Inc. | Geiger Jesse J60 | President | Sell | 2,558 | $393.51 | $1,006,585.79 | -40.1% | -2.4% | -17.7% | |
| Feb 29, 2024 | TMO Thermo Fisher Scientific Inc. | Casper Marc N59 | Chairman &CEO | Sell | 10,000 | $571.08 | $5,710,818.16 | -1.5% | -0.5% | -7.2% | |
| Feb 29, 2024 | CRL Charles River Laboratories International, Inc. | Creamer Victoria L65 | EVP &Chief People Officer | Sell | 5,000 | $253.70 | $1,268,500.00 | -27.0% | -16.8% | -35.0% | |
| Feb 29, 2024 | IQV Iqvia Holdings Inc. | Staub W Richard | See Remarks | Sell | 14,100 | $247.80 | $3,494,034.00 | -20.4% | -9.0% | -23.6% | |
| Feb 29, 2024 | NTRA Natera, Inc. | Rabinowitz Daniel48 | Sec. And Chief Legal Officer | Sell | 55,833 | $80.21 | $4,478,268.39 | -4.9% | +27.0% | +79.9% | |
| Feb 28, 2024 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 500,000 | $0.99 | $496,150.00 | +0.2% | +38.0% | +65.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.